Canton Strategic Holdings CEO Mark Wendland Joins Canton Foundation Board, Tharimmune Reports Clinical-Stage Biotechnology Advancements.

Tuesday, Mar 3, 2026 3:11 pm ET1min read
CNTN--

Canton Strategic Holdings, Inc. chairman and CEO Mark Wendland has been elected to the Canton Foundation board. Tharimmune, Inc. is a clinical-stage biotech company developing therapeutic candidates for inflammatory and immunologic conditions. They have a Phase I clinical trial for TH104, a transmucosal film product, and preclinical development for two bispecific candidates and a Picobody candidate.

Canton Strategic Holdings CEO Mark Wendland Joins Canton Foundation Board, Tharimmune Reports Clinical-Stage Biotechnology Advancements.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet